{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T12:21:49Z","timestamp":1784031709995,"version":"3.55.0"},"reference-count":31,"publisher":"Walter de Gruyter GmbH","issue":"4","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To test the hypothesis that clinical tumor response after a single cycle of induction chemotherapy (ICT) can reliably differentiate between chemo-\/radiosensitive and resistant tumors in the larynx preservation setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>Treatment consisted of docetaxel\/cisplatin\/5-fluorouracil (TPF) ICT followed by concurrent chemoradiotherapy (cCRT) with weekly cisplatin. The response of the primary tumor was assessed by transnasal endoscopy after the first ICT cycle.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>37\/39 (95%) patients with laryngeal (46%) or hypopharyngeal (54%) carcinoma responded to one cycle of ICT, and two patients were referred for salvage surgery. Laryngectomy-free survival at 2 and 5 years was 87% and 75%, respectively. The corresponding rates for locoregional control (and also for disease-free survival) were 79% and 70% and for overall survival 92% and 82%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Clinical assessment of tumor response to one cycle of TPF ICT serves as a valid and easy-to-use predictor of tumor sensitivity to platinum-based cCRT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/raon-2025-0055","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T09:01:49Z","timestamp":1761555709000},"page":"579-588","source":"Crossref","is-referenced-by-count":1,"title":["Induction chemotherapy and concurrent chemoradiotherapy for larynx preservation in laryngeal and hypopharyngeal cancer"],"prefix":"10.2478","volume":"59","author":[{"given":"Primoz","family":"Strojan","sequence":"first","affiliation":[{"name":"Institute of Oncology Ljubljana , Ljubljana , Slovenia"},{"name":"University of Ljubljana, Faculty of Medicine , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaber","family":"Plavc","sequence":"additional","affiliation":[{"name":"Institute of Oncology Ljubljana , Ljubljana , Slovenia"},{"name":"University of Ljubljana, Faculty of Medicine , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Sifrer","sequence":"additional","affiliation":[{"name":"University of Ljubljana, Faculty of Medicine , Ljubljana , Slovenia"},{"name":"Department of Otorhinolaryngology and Cervicofacial Surgery, University Medical Centre Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Jereb","sequence":"additional","affiliation":[{"name":"Institute of Oncology Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bostjan","family":"Lanisnik","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology - Head and Neck Surgery, University Medical Center Maribor , Maribor , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Kokalj","sequence":"additional","affiliation":[{"name":"Institute of Oncology Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ales","family":"Groselj","sequence":"additional","affiliation":[{"name":"University of Ljubljana, Faculty of Medicine , Ljubljana , Slovenia"},{"name":"Department of Otorhinolaryngology and Cervicofacial Surgery, University Medical Centre Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cvetka Grasic","family":"Kuhar","sequence":"additional","affiliation":[{"name":"Institute of Oncology Ljubljana , Ljubljana , Slovenia"},{"name":"University of Ljubljana, Faculty of Medicine , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"2026071215564944342_j_raon-2025-0055_ref_001","doi-asserted-by":"crossref","unstructured":"Singer S, Danker H, Guntinas-Lichius O, Oeken J, Pabst F, Schock J, et al. Quality of life before and after total laryngectomy: results of a multicenter prospective cohort study. Head Neck 2014; 36: 359-68. doi: org\/10.1002\/hed.23305","DOI":"10.1002\/hed.23305"},{"key":"2026071215564944342_j_raon-2025-0055_ref_002","doi-asserted-by":"crossref","unstructured":"Argiris A, Lefebvre JL. Laryngeal preservation strategies in locally advanced laryngeal and hypopharyngeal cancers. Front Oncol 2019; 9: 419. doi: org\/10.3389\/fonc.2019.00419","DOI":"10.3389\/fonc.2019.00419"},{"key":"2026071215564944342_j_raon-2025-0055_ref_003","doi-asserted-by":"crossref","unstructured":"Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091-8. doi: 10.1056\/NEJMoa031317","DOI":"10.1056\/NEJMoa031317"},{"key":"2026071215564944342_j_raon-2025-0055_ref_004","doi-asserted-by":"crossref","unstructured":"Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 2013; 31: 845-52. doi: org\/10.1200\/JCO.2012.43.6097","DOI":"10.1200\/JCO.2012.43.6097"},{"key":"2026071215564944342_j_raon-2025-0055_ref_005","doi-asserted-by":"crossref","unstructured":"Strojan P, Haigentz M Jr, Bradford CR, Wolf GT, Hartl DM, Langendijk JA, et al. Chemoradiotherapy vs. total laryngectomy for primary treatment of advanced laryngeal squamous cell carcinoma. Oral Oncol 2013; 49: 283-6. doi: org\/10.1016\/j.oraloncology.2012.11.002","DOI":"10.1016\/j.oraloncology.2012.11.002"},{"key":"2026071215564944342_j_raon-2025-0055_ref_006","doi-asserted-by":"crossref","unstructured":"Kiong KL, de Souza NN, Sultana R, Iyer NG. Meta-analysis of induction chemotherapy as a selection marker for chemoradiation in the head and neck. Laryngoscope 2018; 128: 1594-601. doi: org\/10.1002\/lary.27011","DOI":"10.1002\/lary.27011"},{"key":"2026071215564944342_j_raon-2025-0055_ref_007","doi-asserted-by":"crossref","unstructured":"Forastiere AA, Ismaila N, Lewin JS, Nathan CA, Adelstein DJ, Eisbruch A, et al. Use of larynx-preservation strategies in the treatment of laryngeal cancer: American Society of Clinical Oncology Clinical Practice Guideline update. J Clin Oncol 2018; 36: 1143-69. doi: org\/10.1200\/JCO.2017.75.7385","DOI":"10.1200\/JCO.2017.75.7385"},{"key":"2026071215564944342_j_raon-2025-0055_ref_008","doi-asserted-by":"crossref","unstructured":"Vidal L, Ben Aharon I, Limon D, Cohen E, Popovtzer A. Role of induction chemotherapy prior to chemoradiation in head and neck squamous cell cancer - systematic review and meta-analysis. Cancer J 2017; 23: 79-83. doi: org\/10.1097\/PPO.0000000000000253","DOI":"10.1097\/PPO.0000000000000253"},{"key":"2026071215564944342_j_raon-2025-0055_ref_009","doi-asserted-by":"crossref","unstructured":"Lefebvre JL, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol 2013; 31: 853-9. doi: org\/10.1200\/JCO.2012.42.3988","DOI":"10.1200\/JCO.2012.42.3988"},{"key":"2026071215564944342_j_raon-2025-0055_ref_010","doi-asserted-by":"crossref","unstructured":"Urba S, Wolf G, Eisbruch A, Worden F, Lee J, Bradford C, et al. Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. J Clin Oncol 2006; 24: 593-8. doi: org\/10.1200\/JCO.2005.01.2047","DOI":"10.1200\/JCO.2005.01.2047"},{"key":"2026071215564944342_j_raon-2025-0055_ref_011","doi-asserted-by":"crossref","unstructured":"Wolf GT, Bellile E, Eisbruch A, Urba S, Bradford CR, Peterson L, et al. Survival rates using individualized bioselection treatment methods in patients with advanced laryngeal cancer. JAMA Otolaryngol Head Neck Surg 2017; 143: 355-66. doi: org\/10.1001\/jamaoto.2016.3669","DOI":"10.1001\/jamaoto.2016.3669"},{"key":"2026071215564944342_j_raon-2025-0055_ref_012","doi-asserted-by":"crossref","unstructured":"Strojan P, Gra\u0161i\u010d Kuhar C, \u017dumer B, Kadivec M, Karner K, Fajdiga I, et al. TPF induction chemotherapy and concomitant irradiation with cisplatin and cetuximab in unresectable squamous cell carcinoma of the head and neck. Head Neck 2014; 36: 1555-61. doi: org\/10.1002\/hed.23506","DOI":"10.1002\/hed.23506"},{"key":"2026071215564944342_j_raon-2025-0055_ref_013","doi-asserted-by":"crossref","unstructured":"Gr\u00e9goire V, Evans M, Le QT, Bourhis J, Budach V, Chen A, et al. Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines. Radiother Oncol 2018; 126: 3-24. doi: org\/10.1016\/j.radonc.2017.10.016","DOI":"10.1016\/j.radonc.2017.10.016"},{"key":"2026071215564944342_j_raon-2025-0055_ref_014","doi-asserted-by":"crossref","unstructured":"Gr\u00e9goire V, Ang K, Budach W, Grau C, Hamoir M, Langendijk JA, et al. Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. Radiother Oncol 2015; 117: 83-90. doi: org\/10.1016\/j. radonc.2015.07.041","DOI":"10.1016\/j.radonc.2015.07.041"},{"key":"2026071215564944342_j_raon-2025-0055_ref_015","doi-asserted-by":"crossref","unstructured":"Beitler JJ, Ridge JA, Vermorken JB, Bradford CR, Strojan P, Saba NF, et al. T4 laryngeal cancer with good function: should we be reluctant to treat without surgery? Int J Radiat Oncol Biol Phys 2018; 102: 400-3. doi: org\/10.1016\/j.ijrobp.2018.03.007","DOI":"10.1016\/j.ijrobp.2018.03.007"},{"key":"2026071215564944342_j_raon-2025-0055_ref_016","doi-asserted-by":"crossref","unstructured":"Lefebvre JL, Ang KK. Larynx Preservation Consensus Panel. Larynx preservation clinical trial design: key issues and recommendations - a consensus panel summary. Head Neck 2009; 31: 429-41. doi: org\/10.1002\/hed.21081","DOI":"10.1002\/hed.21081"},{"key":"2026071215564944342_j_raon-2025-0055_ref_017","doi-asserted-by":"crossref","unstructured":"Wichmann G, Kr\u00fcger A, Boehm A, Kolb M, Hofer M, Fischer M, et al. Induction chemotherapy followed by radiotherapy for larynx preservation in advanced laryngeal and hypopharyngeal cancer: outcome prediction after one cycle induction chemotherapy by a score based on clinical evaluation, computed tomography-based volumetry and 18F-FDG-PET\/CT. Eur J Cancer 2017; 72: 144-55. doi: org\/10.1016\/j.ejca.2016.11.013","DOI":"10.1016\/j.ejca.2016.11.013"},{"key":"2026071215564944342_j_raon-2025-0055_ref_018","doi-asserted-by":"crossref","unstructured":"Popovtzer A, Burnstein H, Stemmer S, Limon D, Hili O, Bachar G, et al. Phase II organ-preservation trial: concurrent cisplatin and radiotherapy for advanced laryngeal cancer after response to docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy. Head Neck 2017; 39: 227-33. doi: org\/10.1002\/hed.24571","DOI":"10.1002\/hed.24571"},{"key":"2026071215564944342_j_raon-2025-0055_ref_019","doi-asserted-by":"crossref","unstructured":"Garcia GCTE, Gorphe P, Hartl D, Ammari S, Even C, Tao Y, et al. Computed tomography evaluation after induction chemotherapy for T3 laryngeal cancer: does response correlate with vocal cord mobility? Oral Oncol 2019; 90: 13-6. doi: 10.1016\/j.oraloncology.2019.01.009","DOI":"10.1016\/j.oraloncology.2019.01.009"},{"key":"2026071215564944342_j_raon-2025-0055_ref_020","doi-asserted-by":"crossref","unstructured":"Ferrari M, Mularoni F, Taboni S, Crosetti E, Pessina C, Carobbio ALC, et al. How reliable is assessment of true vocal cord-arytenoid unit mobility in patients affected by laryngeal cancer? A multi-institutional study on 366 patients from the ARYFIX collaborative group. Oral Oncol 2024; 152: 106744. doi: 10.1016\/j.oraloncology.2024.106744","DOI":"10.1016\/j.oraloncology.2024.106744"},{"key":"2026071215564944342_j_raon-2025-0055_ref_021","doi-asserted-by":"crossref","unstructured":"de Bree R, Wolf GT, de Keizer B, Nixon IJ, Hartl DM, Forastiere AA, et al. Response assessment after induction chemotherapy for head and neck squamous cell carcinoma: from physical examination to modern imaging techniques and beyond. Head Neck 2017; 39: 2329-49. doi: 10.1002\/hed.24883","DOI":"10.1002\/hed.24883"},{"key":"2026071215564944342_j_raon-2025-0055_ref_022","doi-asserted-by":"crossref","unstructured":"Xu J, Yang Y, Zhong Q, Hou L, Ma H, Zhang Y, et al. A study of peripheral blood parameters to predict response to induction chemotherapy and overall survival in advanced laryngeal squamous cell carcinoma. Curr Oncol 2022; 29: 6472-84. doi: 10.3390\/curroncol29090509","DOI":"10.3390\/curroncol29090509"},{"key":"2026071215564944342_j_raon-2025-0055_ref_023","doi-asserted-by":"crossref","unstructured":"Tan C, Wang L, Yang Y, He S, Chen GG, Chan JY, et al. Construction of a novel six-gene signature to predict tumour response to induction chemotherapy and overall survival in locoregionally advanced laryngeal and hypopharyngeal carcinoma. Genes Dis 2023; 11: 101022. doi: 10.1016\/j. gendis.2023.05.018","DOI":"10.1016\/j.gendis.2023.05.018"},{"key":"2026071215564944342_j_raon-2025-0055_ref_024","doi-asserted-by":"crossref","unstructured":"Janoray G, Pointreau Y, Garaud P, Chapet S, Alfonsi M, Sire C, et al. Long-term results of a multicenter randomized phase III trial of induction chemotherapy with cisplatin, 5-fluorouracil, \u00b1 docetaxel for larynx preservation. J Natl Cancer Inst 2016; 108: djv368. doi: 10.1093\/jnci\/djv368","DOI":"10.1093\/jnci\/djv368"},{"key":"2026071215564944342_j_raon-2025-0055_ref_025","doi-asserted-by":"crossref","unstructured":"Dietz A, Wichmann G, Kuhnt T, Pfreundner L, Hagen R, Scheich M, et al. Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal\/hypopharyngeal cancer resectable only by total laryngectomy: final results of the larynx organ preservation trial DeLOS-II. Ann Oncol 2018; 29: 2105-14. doi: 10.1093\/annonc\/mdy332","DOI":"10.1055\/s-0038-1640003"},{"key":"2026071215564944342_j_raon-2025-0055_ref_026","doi-asserted-by":"crossref","unstructured":"Sanabria A, Chaves ALF, Kowalski LP, Wolf GT, Saba NF, Forastiere AA, et al. Organ preservation with chemoradiation in advanced laryngeal cancer: the problem of generalizing results from randomized controlled trials. Auris Nasus Larynx 2017; 44: 18-25. doi: 10.1016\/j.anl.2016.06.005","DOI":"10.1016\/j.anl.2016.06.005"},{"key":"2026071215564944342_j_raon-2025-0055_ref_027","doi-asserted-by":"crossref","unstructured":"Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al; EORTC 24971\/TAX 323 Study Group. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357: 1695-704. doi: 10.1056\/NEJMoa071028","DOI":"10.1056\/NEJMoa071028"},{"key":"2026071215564944342_j_raon-2025-0055_ref_028","doi-asserted-by":"crossref","unstructured":"Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, et al; TAX 324 Study Group. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357: 1705-15. doi: org\/10.1056\/NEJMoa070956","DOI":"10.1056\/NEJMoa070956"},{"key":"2026071215564944342_j_raon-2025-0055_ref_029","doi-asserted-by":"crossref","unstructured":"Peng J, Luo G, Yu Y, Ning K, Liu X. Retrospective assessment of neoadjuvant camrelizumab combined with induction chemotherapy: efficacy in laryngeal preservation for advanced hypopharyngeal and laryngeal squamous cell carcinoma. Cancer Immunol Immunother 2024; 73: 54. doi: org\/10.1007\/s00262-023-03579-0","DOI":"10.1007\/s00262-023-03579-0"},{"key":"2026071215564944342_j_raon-2025-0055_ref_030","doi-asserted-by":"crossref","unstructured":"Chow LQM. Head and neck cancer. N Engl J Med 2020; 382: 60-72. doi: org\/10.1056\/NEJMra1715715","DOI":"10.1056\/NEJMra1715715"},{"key":"2026071215564944342_j_raon-2025-0055_ref_031","doi-asserted-by":"crossref","unstructured":"Janoray G, Pointreau Y, Alfonsi M, Sire C, Geoffrois L, de Raucourt D, et al. Induction chemotherapy followed by cisplatin or cetuximab concomitant to radiotherapy for laryngeal\/hypopharyngeal cancer: long-term results of the TREMPLIN randomised GORTEC trial. Eur J Cancer 2020; 133: 86-93. doi: 10.1016\/j.ejca.2020.04.009","DOI":"10.1016\/j.ejca.2020.04.009"}],"container-title":["Radiology and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/raon-2025-0055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T22:57:27Z","timestamp":1783897047000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/raon-2025-0055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,10,27]]},"published-print":{"date-parts":[[2025,12,1]]}},"alternative-id":["10.2478\/raon-2025-0055"],"URL":"https:\/\/doi.org\/10.2478\/raon-2025-0055","relation":{},"ISSN":["1581-3207"],"issn-type":[{"value":"1581-3207","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]}}}